 CureVac NASDAQ:CVAC has filed a patent lawsuit in Germany against BioNTech NASDAQ:BNTX in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development, and is seeking fair compensation from BioNTech and two subsidiaries. 